CN118974258A - 抗fap-alpha的人源抗体 - Google Patents

抗fap-alpha的人源抗体 Download PDF

Info

Publication number
CN118974258A
CN118974258A CN202280092987.7A CN202280092987A CN118974258A CN 118974258 A CN118974258 A CN 118974258A CN 202280092987 A CN202280092987 A CN 202280092987A CN 118974258 A CN118974258 A CN 118974258A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
sequence shown
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280092987.7A
Other languages
English (en)
Chinese (zh)
Inventor
杨柳
蒋雯卿
方磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lepu Biotechnology Co ltd
Original Assignee
Lepu Biotechnology Co ltd
Lepu Chuangyi Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lepu Biotechnology Co ltd, Lepu Chuangyi Biotechnology Shanghai Co ltd filed Critical Lepu Biotechnology Co ltd
Priority to CN202511419738.6A priority Critical patent/CN121342995A/zh
Publication of CN118974258A publication Critical patent/CN118974258A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4247—Proteinases
    • A61K40/4249—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280092987.7A 2021-12-30 2022-12-29 抗fap-alpha的人源抗体 Pending CN118974258A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511419738.6A CN121342995A (zh) 2021-12-30 2022-12-29 抗FAP-Alpha的人源抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021143087 2021-12-30
CNPCT/CN2021/143087 2021-12-30
PCT/CN2022/143358 WO2023125796A1 (en) 2021-12-30 2022-12-29 Human antibodies against fap-alpha

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511419738.6A Division CN121342995A (zh) 2021-12-30 2022-12-29 抗FAP-Alpha的人源抗体

Publications (1)

Publication Number Publication Date
CN118974258A true CN118974258A (zh) 2024-11-15

Family

ID=86998178

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280092987.7A Pending CN118974258A (zh) 2021-12-30 2022-12-29 抗fap-alpha的人源抗体
CN202511419738.6A Pending CN121342995A (zh) 2021-12-30 2022-12-29 抗FAP-Alpha的人源抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511419738.6A Pending CN121342995A (zh) 2021-12-30 2022-12-29 抗FAP-Alpha的人源抗体

Country Status (5)

Country Link
US (1) US20250297032A1 (https=)
EP (1) EP4457346A1 (https=)
JP (1) JP2025503533A (https=)
CN (2) CN118974258A (https=)
WO (1) WO2023125796A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120309735A (zh) * 2024-01-15 2025-07-15 迈威(上海)生物科技股份有限公司 重组抗fap抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
CN111118063A (zh) * 2019-12-05 2020-05-08 吉林大学 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
EP1268550A2 (en) * 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
DE10013286A1 (de) * 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Humane FAP-alpha-spezifische Antikörper
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
CN109796532B (zh) * 2017-11-17 2024-09-10 恺兴生命科技(上海)有限公司 靶向成纤维激活蛋白α的结合单元及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
CN111118063A (zh) * 2019-12-05 2020-05-08 吉林大学 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用

Also Published As

Publication number Publication date
CN121342995A (zh) 2026-01-16
WO2023125796A1 (en) 2023-07-06
JP2025503533A (ja) 2025-02-04
US20250297032A1 (en) 2025-09-25
EP4457346A1 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
AU2020291012B2 (en) Novel IL-15 prodrugs and methods of use thereof
Strohl Current progress in innovative engineered antibodies
WO2023116880A1 (en) Anti-ccr8 antibodies and uses thereof
CN120623346A (zh) Pd-1单结构域抗体及其治疗组合物
CN118317975A (zh) 靶向baff-r的抗体及其用途
CN121620527A (zh) 针对gprc5d的单域抗体
CN119451988B (zh) 抗b7-h3抗体及其用途
JP2026506563A (ja) Ｌｉｖ－１を標的とする抗体およびその使用
CN119735678B (zh) 肿瘤抗原依赖性cd40激动剂单域抗体
CN118974258A (zh) 抗fap-alpha的人源抗体
JP2025506248A (ja) 抗５ｔ４抗体およびその使用
CN119654342B (zh) 抗MerTK抗体及其用途
HK40117638A (zh) 抗fap-alpha的人源抗体
HK40117975A (zh) 抗b7-h3抗体及其用途
HK40117975B (zh) 抗b7-h3抗体及其用途
WO2025061132A1 (en) Anti-dll3 antibodies and uses thereof
TW202535953A (zh) 靶向密連蛋白６之抗體及抗體－藥物結合物
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof
TW202535936A (zh) 靶向liv-1之抗體及其用途
JP2026501783A (ja) Ｓｍａｇｐ融合分子およびその使用方法
HK40112932A (zh) 抗5t4抗体及其用途
EP4475880A2 (en) Anti-il13ra2 antibodies and uses thereof
TW202602939A (zh) 一種多特異性抗體t細胞銜接器

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40117638

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20251015

Address after: 201114 Shanghai Minhang District, Su Zhao Road No. 1628, Building 1, Room C280

Applicant after: Lepu Biotechnology Co.,Ltd.

Country or region after: China

Address before: 201203 Shanghai Pudong New Area Zhangheng Road 1077, Room B207 Dade Chuangtong

Applicant before: Lepu Chuangyi Biotechnology (Shanghai) Co.,Ltd.

Country or region before: China

Applicant before: Lepu Biotechnology Co.,Ltd.

TA01 Transfer of patent application right